University of Minnesota
Minneapolis, Minnesota, 55455, United States
NCT Number: NCT07573306
This study will establish the feasibility and preliminary validity of real-time oxygen delivery index (DO₂i) monitoring using noninvasive hemoglobin (SpHb, Masimo) and minimally invasive cardiac output (FloTrac, Edwards) in cardiac surgery patients.
Trial opening soon.
Get Notified18 year and older
All sexes
Observational
Minneapolis, Minnesota, 55455, United States
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
The SpHb monitor is an FDA approved device being used according to its approved indications. No additional invasive procedures, blood draws, or interventions are performed for research purposes.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post-protamine
Bias and 95% limits of agreement between monitor-derived DO₂i (calculated from continuous SpHb and FloTrac cardiac index) and pulmonary artery catheter DO₂i (calculated from arterial blood gas hemoglobin and Swan-Ganz cardiac index), analyzed using Bland-Altman method with mixed-effects modeling to account for repeated measures. Agreement is considered acceptable if percentage error is <30%.
Time frame: Changes between consecutive intraoperative timepoints (baseline to post-heparin, post- heparin to post-protamine) during cardiac surgery
Four-quadrant concordance rate (with 15% exclusion zone) for directional changes in DO₂i between consecutive timepoints. Concordance is defined as agreement in direction of change (increase vs decrease) between monitor-derived and gold-standard DO₂i measurements. Scores range from 0- 100%, with higher percentages indicating better directional agreement.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
Pearson or Spearman correlation coefficient between DO₂i (both monitor-derived and gold- standard) and simultaneously measured arterial lactate concentration. Correlation coefficients range from -1 to +1, with negative values indicating inverse relationship between DO₂i and lactate.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
Percentage error between FloTrac arterial pressure-based cardiac index and Swan-Ganz thermodilution continuous cardiac index. Percentage error is calculated as (1.96 × SD of differences) / mean cardiac index × 100%. Agreement is considered acceptable if percentage error is <30%.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
Comparison of limits of agreement before and after in vivo SpHb calibration (baseline- adjusted SpHb using first arterial blood gas hemoglobin value as reference). Measured as change in bias and 95% limits of agreement between uncalibrated and baseline-calibrated SpHb-based DO₂i compared to gold standard.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
Percentage of planned timepoints with valid SpHb signal defined by perfusion index (PI) ≥ 0.5. Scores range from 0-100%, with 100% indicating valid signal at all timepoints.
Time frame: Three intraoperative timepoints during cardiac surgery: baseline, post-heparin, and post- protamine
Minimum perfusion index value associated with acceptable SpHb accuracy, defined as SpHb bias within ±1 g/dL of arterial blood gas hemoglobin. Perfusion index values range from 0-20%, with higher values indicating better peripheral perfusion.
Time frame: Within 30 days of surgery
Composite endpoint including all-cause mortality, myocardial infarction (elevated troponin with ECG changes or clinical symptoms), stroke (new neurologic deficit with imaging confirmation), or urgent revascularization.
Time frame: Within 30 days of surgery
AKI defined and staged using KDIGO criteria based on postoperative serum creatinine changes: Stage 1 (1.5-1.9× baseline or ≥0.3 mg/dL increase), Stage 2 (2.0-2.9× baseline), Stage 3 (≥3× baseline or ≥4.0 mg/dL or initiation of renal replacement therapy).
Contact information is provided by the study sponsor or research team.
University of Minnesota
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT07771751
Agnosia, Cardiac Surgery
Istanbul, Sancaktepe, Turkey (Türkiye)
View Trial DetailsNCT07766109
Cardiac Surgery, Cardiovascular Diseases
Toulouse, France
View Trial DetailsNCT07757880
Cardiac Surgery
Boston, Massachusetts, United States
View Trial DetailsNCT07729280
Cardiac Surgery, Glucose Metabolism Disorders
Sleman, D.I. Yogyakarta, Indonesia
View Trial Details